CD8A and neoplasm: Against the background that TRAF2 and cIAPs ([250,254]) protect tumor cells against the cytotoxic action of CD8+ T-cells and NK cells after ICB, combination therapies of TRAF2 inhibitors and checkpoint inhibitors appears particularly interesting.